Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP).

Trial Profile

Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Imatinib; Vatalanib
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2012 Actual patient number is 9 according to ClinicalTrials.gov.
    • 19 Jan 2012 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 24 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top